wheezo is your asthma personal assistant. It helps you better understand how asthma affects you so you can do all the things you love doing. You can log how your breathing feels, symptoms and triggers and medication usage. You can also set medication reminders to help improve asthma control. When it’s time to visit your doctor, wheezo will provide a simple and accessible picture of your asthma history. wheezo helps you manage your asthma worries. Features:
Self-assessment - Log how your breathing feels, your symptoms and any triggers throughout the day.
Log Medication – Record your preventer and reliever use and set reminders for better asthma control.
View History – See how your asthma is tracking over time and share it with your doctor.
Respiri limited (ASX: RSH) (“Respiri” or the “Company”) is pleased to announce a joint venture agreement for the company’s entry into India with MedAchievers Private Limited (“MedAchievers”) – an integrated platform for global healthcare. Dr Harsha Vardhan is the Founder and Group Managing Director, and the Joint Venture will be supported by Australian- India business trade expert Mr Michael Koss.
For Respiri to successfully enter India, it is of critical importance to identify the best possible local healthcare leaders with key relationships in Tier 1 and 2 private hospitals (hospital owners, lead pulmonologists etc). From this perspective, the company is delighted with the progress achieved to date in working with MedAchievers, Dr Harsha Vardhan and Mr Michael Koss. Respiri and MedAchievers have a clearly defined market engagement strategy that is targeting first Indian sales in October/November.
Thursday, May 9, 2019
Respiri’s innovative devices and apps use digital wheeze detection and measurement technology, replacing outdated and difficult-to-use instruments for lung function testing such as peak flow meters.
Respiri’s clinically proven patented technology is used in major hospitals in UK, Europe, USA, Japan, Korea and Australia.
Respiri operates in an industry subset of the globally attractive health and technology sectors and is well positioned as one of the few companies in the world producing the next wave of consumer focused technology for complex disease management.
Our unique proprietary Acoustic Respiratory Monitoring (ARM™) technology records airway sounds to detect continuous adventitious breath sounds (CABS) and measure the extent of wheezing caused by airway obstruction.
Respiri devices work like a stethoscope, utilizing contact sensors to acquire breath sounds at the windpipe (trachea).
Respiri Limited (ASX:RSH) is an Australian owned company with revolutionary smart tools to empower people with asthma and improve outcomes. For over 330 million people worldwide, the simple act of breathing can be a terrifying daily ordeal. Asthma affects quality of life, productivity at work and school and at its worse, still kills. Backed by over twenty years of research by respiratory specialists, and with first-move advantage, Respiri offers an over-the-counter monitoring solution that will help people manage asthma in ways that have never been available before.
January 9, 2020
The COVID-19 pandemic is making capital harder to come by for businesses across the board.
But listed health-tech platform Respiri (ASX:RSH) still managed to close the deal, announcing the completion of its $2m share placement yesterday.
Amid the broader market turbulence, Respiri’s offer found demand from sophisticated investors who snapped up a total of 36,363,637 shares priced at 5.5c.
Source: Stockhead
The coronavirus-induced market carnage of the last few weeks has rattled plenty of investor nerves.
But as with any major correction, some industries feel the brunt of the impact while for others, the dramatic shift presents an opportunity.
Source: Stockhead
A majority of people who think they have their asthma under control are wrong and are putting themselves at serious risk of severe and potentially life-threatening flare-ups during this unprecedented bushfire season.
Respiri is pleased to announce it has earned Frost & Sullivan’s 2019 European Smart Healthcare Technology Award for ‘its strong overall performance and commendable technology leverage’.
Frost & Sullivan Best Practices Awards are independent, research backed accolades that
recognise companies throughout a range of regional and global markets. Its industry analyst team benchmarks market participants and measures their performance through independent primary interviews and secondary industry research in order to evaluate and identify best practices.
Frost & Sullivan analysts independently evaluated the performance of Respiri and other companies in healthcare technology on two key factors – Technology Attributes and Future Business Value.
To support its evaluation of best practices across multiple business performance categories, Frost & Sullivan employs a customised Decision Support Scorecard to allow research and consulting teams to objectively analyse performance according to key benchmarking criteria and to assign ratings on that basis. Respiri rated well above its identified competitors to secure the 2019 Best Practices Award.
About one in nine Australians – 2.7 million people – suffer from asthma, according to the Australian Institute of Health and Welfare. At least 421 people died from the disease in 2015 and the mortality rate is stubbornly hard to shift.
Medical technology innovator Respiri aims to change this with a new connected device, dubbed wheezo®, which records breath sounds to detect and measure ‘‘wheeze rate’’ – the extent of the coarse whistling sound produced when the airways are narrowed and inflamed.
